According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move that could potentially reap about $5 billion.
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)
Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.
Copyright © 2016-2018 Drugdu.com. All Rights Reserved.